The Protein Study
The study drug is a potential new treatment for systemic amyloidosis.
Systemic amyloidosis is a condition where proteins (amyloid) build up in tissues and organs, resulting in organ failure. It can be hard to detect in the body as symptoms are non-specific and slow to develop.
The study drug may potentially reverse organ damage that is caused by systemic amyloidosis, it works differently to the currently treatment options and is administered as an IV infusion.
Systemic amyloidosis still requires more effective treatment options, it is hope that the study drug can help to improve survival and improved quality of life of people with systemic amyloidosis.
This clinical trial has been approved by an independent ethics committee, and you will be reimbursed for your time.